{"id":"arxiv:2112.01081","kind":"article","title":"Matrix metalloproteinases as new targets in Alzheimer's disease: Opportunities and Challenges","authors":["Pauline Zipfel","Christophe Rochais","Kévin Baranger","Santiago Rivera","Patrick Dallemagne"],"author_count":5,"year":2021,"published":"2021-12-02","venue":"Journal of Medicinal Chemistry, American Chemical Society, 2020","cited_by":94,"doi":"10.1021/acs.jmedchem.0c00352","arxiv_id":"2112.01081","nct_id":null,"source_url":"https://arxiv.org/abs/2112.01081","archive_url":"https://space-kitty.com/papers/arxiv:2112.01081","updated":"2021-12-02","pmid":null,"pmcid":null,"openalex_id":"W3029030457","pdf_url":"https://arxiv.org/pdf/2112.01081","abstract":"Although matrix metalloproteinases (MMPs) are implicated in the regulation of numerous physiological processes, evidences of their pathological roles have also been obtained in the last decades, making MMPs attractive therapeutic targets for several diseases. Recent discoveries of their involvement in central nervous system (CNS) disorders, and in particular in Alzheimer's disease (AD), have paved the way to consider MMP modulators as promising therapeutic strategies. Over the past few decades, diverse approaches have been undertaken in the design of","abstract_license":"CC0-1.0 (arXiv descriptive metadata)","license":null,"is_open_access":false,"retracted":false,"peer_reviewed":null,"categories":["q-bio.NC"],"details":null,"provenance":"arxiv","attribution":"Abstract: arXiv descriptive metadata (CC0). Thank you to arXiv for use of its open access interoperability. This service was not reviewed or approved by, nor does it necessarily express or reflect the policies or opinions of, arXiv.","topics":[{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","domain_slug":"medicine"}],"cited_in_dossiers":[]}